Class Actions
Shoals Technologies Group, Inc. Class Action
Robbins LLP is Investigating the Allegations that Shoals Technologies Group, Inc. (SHLS) Delivered Defective Products
March 22, 2024
THE NEWSROOM
Search
Categories
Archives
Investment Monitoring From Robbins LLP
To ensure your financial investments are being managed honestly, enroll in Stock Watch, our free investment monitoring service for individual and institutional investors.
Class Actions
The Chemours Company Class Action
Robbins LLP is Investigating the Allegations that The Chemours Company (CC) Had Deficient Accounting Practices and Procedures
March 22, 2024
Investigations
The Estee Lauder Companies, Inc.
Robbins LLP is Investigating the Officers and Directors of The Estee Lauder Companies Inc. (EL) on Behalf of Shareholders
March 21, 2024
Class Actions
agilon health, inc. Class Action
Robbins LLP is Investigating the Allegations that agilon health, inc. (AGL) Misled Investors Regarding Medical Costs
March 20, 2024
Class Actions
SSR Mining Inc. Class Action
Robbins LLP is Investigating the Allegations that SSR Mining Inc. (SSRM) Misled Investors Regarding its Safety Practices
March 19, 2024
Class Actions
Innoviz Technologies Ltd. Class Action
Robbins LLP is Investigating the Allegations that Innoviz Technologies Ltd. (INVZ) Misled Investors Regarding the Profitability of its Purported Contracts
March 18, 2024
Class Actions
Next Bridge Hydrocarbons, Inc.
Robbins LLP is Investigating the Allegations that Next Bridge Hydrocarbons, Inc. Made False and Misleading Statements in its Registration Statement Relating to the Spin-Off of its Oil and Gas Assets
March 17, 2024
Investigations
HireRight Holdings Corp.
Robbins LLP is Investigating the Acquisition of HireRight Holdings Corp. (HRT) by General Atlantic, L.P. and Stone Point Capital LLC
March 14, 2024
Class Actions
Avanex Life Sciences Corporation Class Action
Robbins LLP is Investigating the Allegations that Anavex Life Sciences Corporation (AVXL) Misled Investors Regarding the Likelihood of Success of its Clinical Trial
March 14, 2024